CAS: 2225148-51-4

Thalidomide-O-C8-COOH, also known as Cereblon ligand 3, is a Thalidomide-derived compound that serves as a Cereblon (CRBN) ligand for the targeted recruitment

Thalidomide-o-C8-COOH is a synthetic derivative of thalidomide, which is a modified compound used primarily in biochemical research. As a derivative of thalidomide, it is synthesized through chemical modification to include an octanoic acid moiety, resulting in a conjugated structure. The compound plays a significant role in the study of protein degradation pathways via the ubiquitin-proteasome system. The mode of action for Thalidomide-o-C8-COOH involves binding to cereblon, a component of the E3 ubiquitin ligase complex, thus influencing protein homeostasis by mediating the degradation of specific target proteins. Its ability to modulate protein interactions makes it useful for mechanistic studies related to targeted protein degradation, a vital process in cellular regulation and cancer research. Thalidomide-o-C8-COOH is leveraged in a variety of experimental frameworks, particularly in studying ligand-induced ubiquitination processes crucial for selectively degrading disease-relevant proteins. Its application extends to cancer biology, where researchers explore its potential for developing therapeutic strategies that exploit the ubiquitin-proteasome system for controlled protein degradation, providing insights into novel drug discovery and development pathways.